Organogenesis Holdings Inc. Earnings Recaps
Q3 2025
Nov 8, 2025
Organogenesis Holdings reported strong third quarter results for 2025, driven by a 31% increase in Advanced Wound Care product sales and strategic advancements in Medicare payment reforms, positioning the company favorably for future growth.
Key takeaways
- Q3 revenues exceeded guidance, with Advanced Wound Care sales up 31% year-over-year and Surgical & Sports Medicine sales climbing 25%.
- The finalization of Medicare physician fee schedules marks a significant development, offering expanded access and potential for higher reimbursement for PMA products.
- Progress on the ReNu program includes favorable clinical results, FDA RMAT designation, and an upcoming meeting scheduled for December to discuss the BLA submission.
- The company maintained its competitive edge through strong brand equity and established customer relationships in the evolving skin substitute market.
- Organogenesis is well-positioned to leverage changes in Medicare policy and drive innovation in regenerative medicine.